CNTA vs. PRVL, SRRK, ALXO, OCGN, VTYX, RARE, HCM, PBH, CORT, and MRUS
Should you be buying Centessa Pharmaceuticals stock or one of its competitors? The main competitors of Centessa Pharmaceuticals include Prevail Therapeutics (PRVL), Scholar Rock (SRRK), ALX Oncology (ALXO), Ocugen (OCGN), Ventyx Biosciences (VTYX), Ultragenyx Pharmaceutical (RARE), HUTCHMED (HCM), Prestige Consumer Healthcare (PBH), Corcept Therapeutics (CORT), and Merus (MRUS). These companies are all part of the "medical" sector.
Prevail Therapeutics (NASDAQ:PRVL) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, community ranking, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.
Centessa Pharmaceuticals' return on equity of -55.57% beat Prevail Therapeutics' return on equity.
Prevail Therapeutics has higher earnings, but lower revenue than Centessa Pharmaceuticals. Prevail Therapeutics is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
86.8% of Prevail Therapeutics shares are held by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 57.2% of Prevail Therapeutics shares are held by company insiders. Comparatively, 11.6% of Centessa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Prevail Therapeutics has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.
In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than Prevail Therapeutics. MarketBeat recorded 2 mentions for Centessa Pharmaceuticals and 0 mentions for Prevail Therapeutics. Prevail Therapeutics' average media sentiment score of 0.34 beat Centessa Pharmaceuticals' score of 0.00 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.
Centessa Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 13.64%. Given Prevail Therapeutics' higher probable upside, analysts clearly believe Centessa Pharmaceuticals is more favorable than Prevail Therapeutics.
Prevail Therapeutics received 26 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 59.74% of users gave Prevail Therapeutics an outperform vote while only 48.78% of users gave Centessa Pharmaceuticals an outperform vote.
Summary
Centessa Pharmaceuticals beats Prevail Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Centessa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Centessa Pharmaceuticals Competitors List
Related Companies and Tools
